GALMED ANNOUNCES FIRST TIME RESULTS IN PROSTATE ONCOLOGY STUDIES: ARAMCHOL DEMONSTRATES 3-4 FOLD INCREASE IN CELL DEATH COMPARED TO ENZALUTAMIDE (XTANDI®) ALONE IN PROSTATE CANCER MODELS

Reuters · 1d ago

Please log in to view news